Back

Improving LDL-C goal attainment: real-world outcomes and the impact of guideline optimization

30 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering (3) Drug therapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Rogina Rached

(Denmark)

5 More presentations in this session

Presentation thumbnail
Statin-free PCSK9 inhibitor therapy versus high-intensity atorvastatin for primary prevention: a target trial emulation study
Associate Professor C. Hsu (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Achievement of LDL‑C targets in clinical practice in Spain: a comparison between Observatory II and Observatory I
Doctor J. Cosin Sales (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Evolocumab for high cardiovascular risk patients without previous stroke: a network meta-analysis of randomized controlled trials
Mr S. Phutinart (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Suboptimal LDL cholesterol target achievement in cardiac ATTR amyloidosis despite disease-modifying therapy
Doctor M. Pollak (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Lipid-lowering therapy use and LDL-C goal achievement in patients with hypercholesterolaemia or mixed dyslipidaemia in Hong Kong: findings from a retrospective database study
Professor B. Yan (Hong Kong, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid lowering (3)

The Event

Event poster

ESC Congress 2026

30 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
How good/bad are we in achieving target LDLs post ACS?
18 March 2022
thumbnail
Congress Presentation
Treatment quality in patients with familial hypercholesterolemia in Denmark
29 August 2025
thumbnail
Congress Presentation
Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort
26 August 2023
thumbnail
Congress Presentation
Current non-HDL cholesterol treatment target insufficiently captures residual cardiovascular risk in very-high risk patients
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources